S Yu1, G Li1, Z Wang1, Z Wang1, C Chen1, S Cai1, Y He1. 1. Department of Gastrointestinal Surgery, First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Street, Guangzhou, 510080, Guangdong Province, People's Republic of China. 2. Department of Gastrointestinal Surgery, First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan 2nd Street, Guangzhou, 510080, Guangdong Province, People's Republic of China. drzhaowang@163.com.
Abstract
INTRODUCTION: The prognostic value of pSTAT3 in gastric cancer has been assessed for years while the results remain controversial and heterogeneous. Therefore, we conducted this meta-analysis to determine the prognostic effect of pSTAT3 in gastric cancer patients. METHODS: We searched PubMed, Embase and Web of Science and eight studies comprising 1314 gastric cancer patients were included in our meta-analysis. Hazard ratios (HRs) with 95 % confidence interval (95 % CI) were extracted to perform meta-analysis on the overall survival. Subgroup analysis according to study location, publication year, number of patients and quality score of studies were also investigated. RESULTS: Our results revealed that pSTAT3-positive patients had a significant increase in mortality risk as compared to pSTAT3-negative patients in the random-effects model (combined HR 1.87, 95 % CI 1.28-2.74). However, our result showed no statistically significant association between pSTAT3 and clinicopathological characteristics (TMN stage, lymph node metastasis, grade of differentiation, Lauren classification and distant metastasis) of gastric cancer. CONCLUSION: In conclusion, our meta-analysis suggests that positive expression of pSTAT3 is associated with poor prognosis in gastric cancer patients.
INTRODUCTION: The prognostic value of pSTAT3 in gastric cancer has been assessed for years while the results remain controversial and heterogeneous. Therefore, we conducted this meta-analysis to determine the prognostic effect of pSTAT3 in gastric cancerpatients. METHODS: We searched PubMed, Embase and Web of Science and eight studies comprising 1314 gastric cancerpatients were included in our meta-analysis. Hazard ratios (HRs) with 95 % confidence interval (95 % CI) were extracted to perform meta-analysis on the overall survival. Subgroup analysis according to study location, publication year, number of patients and quality score of studies were also investigated. RESULTS: Our results revealed that pSTAT3-positive patients had a significant increase in mortality risk as compared to pSTAT3-negative patients in the random-effects model (combined HR 1.87, 95 % CI 1.28-2.74). However, our result showed no statistically significant association between pSTAT3 and clinicopathological characteristics (TMN stage, lymph node metastasis, grade of differentiation, Lauren classification and distant metastasis) of gastric cancer. CONCLUSION: In conclusion, our meta-analysis suggests that positive expression of pSTAT3 is associated with poor prognosis in gastric cancerpatients.
Authors: James V Alvarez; Heidi Greulich; William R Sellers; Matthew Meyerson; David A Frank Journal: Cancer Res Date: 2006-03-15 Impact factor: 12.701